Skip to main content

Fiscal Wizard · Single-issue tearsheet

PDSB / Jun 22, 2026 Run #7690

PDSB

PDS Biotechnology Corporation

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Composite verdict

F 15.8 / 100
Bearish setup · Trend Following 13 drivers · 7 gates blocking
  • Rate of Change
  • Vortex Signal
  • TRIX Zero-Line
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 341st of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

31.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Free Cash Flow Yield 0
P/B 75
Greenblatt EY 17
Return on Capital Employed 17

Technicals Bearish

0.0 / 100

Bearish setup leads (Rate of Change, Vortex Signal, TRIX Zero-Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 5
Vortex Signal 12
Elder Force Index 17

Risk Gates

7 blocking 4 caution

7 guards active, 21 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for PDSB.